![](https://investorshub.advfn.com/uicon/515354.png?cb=1605015277)
Wednesday, May 20, 2020 5:56:01 PM
Maybe it's time to re-read about the SK trial in black and white?
The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia. Patients are randomized in a 1:1 fashion to receive either standard of care (SOC) or SOC with Ifenprodil. The primary endpoint will be the rate at which their lung function improves by measuring oxygen levels in the blood (Pa02/Fi02). Secondary endpoints will include mortality, rate of mechanical ventilation, and patient reported effects on cough and breathlessness (dyspnea).
Enrollment in the phase 2 clinical trial is expected to begin on May 8, 2020.
“This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program,” said Christopher J. Moreau CEO of Algernon. “Positive Phase 2 data would be an important milestone as we continue to investigate Ifenprodil’s therapeutic potential as a treatment for COVID-19, in addition to advancing our idiopathic pulmonary fibrosis and chronic cough program.”
Also, as far as the "multinational" clinical trial (Canada/USA/ Australia) for COVID19, I wouldn't expect anything to start prior to Fall 2020. As we can see, management waited for Canadian approval before submitting to Australia. I assume they will wait for approval from Australia before submitting to USA. So full approval by all countries could be months away. Potentially, just in time for the next COVID19 wave to sweep across the USA.
Review 2:35 to 3:25 min/sec mark of latest proactive video.
Moreau explains the strategy behind the "multinational" clinical trial regarding potential difficulties of patient enrollment. I would not be surprised IF their having trouble enrolling patients in SK. I also would not be surprised if that's another reason for the sell off.
SK is said to be the global standard for COVID containment per the World Health Organization.
Algernon couldn't have picked a worse country for a COVID trial at this point in time.
I still don't get why they didn't go at Japan as well for the initial COVID study.
Just 1 opinion,
/////AMG
FEATURED Element79 Gold Corp Appoints Warren Levy to Board of Directors • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM